Section Arrow
ALT.NASDAQ
- Altimmune
Quotes are at least 15-min delayed:2026/03/21 10:09 EDT
Regular Hours
Last
 3.34
-0.08 (-2.34%)
Day High 
3.52 
Prev. Close
3.42 
1-M High
4.83 
Volume 
12.52M 
Bid
3.38
Ask
3.48
Day Low
3.31 
Open
3.43 
1-M Low
3.34 
Market Cap 
428.29M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.62 
20-SMA 3.95 
50-SMA 4.44 
52-W High 7.73 
52-W Low 2.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.00/-1.20
Enterprise Value
463.72M
Balance Sheet
Book Value Per Share
1.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
41.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AZTRAzitra0.2828+0.1067+60.59%-- 
LNAILunai Bioworks Inc.0.4685+0.0835+21.69%-- 
DRMADermata Therapeutics Inc1.46+0.25+20.66%0.09PE
GERNGeron Corp1.46-0.09-5.81%-- 
IBRXImmunityBio8.47-0.35-3.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.